Top-News

ADC Therapeutics Aktie News

Aktie
WKN:  A2PSR8 ISIN:  CH0499880968 US-Symbol:  ADCT Branche:  Biotechnologie Land:  Schweiz
3,29 $
-0,25 $
-7,06%
2,8255 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
337,96 Mio. €
Streubesitz
27,10%
KGV
-1,33
Index-Zuordnung
-

ADC Therapeutics News

15.05.25 - PR Newswire
ADC Therapeutics to Present at Upcoming Investor Conferences
ADC Therapeutics to Present at Upcoming Investor Conferences PR Newswire
14.05.25 - PR Newswire
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update PR Newswire
14.05.25 - PR Newswire
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International ...
08.05.25 - PR Newswire
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 PR Newswire
28.04.25 - PR Newswire
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 PR Newswire
01.04.25 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire
01.04.25 - PR Newswire
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference PR Newswire
27.03.25 - PR Newswire
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update PR Newswire
25.03.25 - PR Newswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 PR Newswire
20.03.25 - PR Newswire
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 PR Newswire
03.02.25 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire
30.01.25 - PR Newswire
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference PR Newswire
02.01.25 - PR Newswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire
30.12.24 - PR Newswire
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell ...
11.12.24 - PR Newswire
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory ...
09.12.24 - PR Newswire
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-​Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat ...
06.12.24 - PR Newswire
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »